Skip to main content
. 2021 Aug 3;13(1):54–64. doi: 10.1111/jdi.13624

Figure 3.

Figure 3

Effects of canagliflozin on intermediate outcomes over time in participants in East and South‐East Asian countries in Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE). Changes in (a) urinary albumin (mg)‐to‐creatinine (g) ratio (UACR) and (b) estimated glomerular filtration rate (eGFR) from baseline. Data are presented as the geometric mean with 95% confidence interval (CI) in (a) and as least square (LS) mean ± standard error (SE).